Improving the procedure for detection of intrahepatic transplanted islets by magnetic resonance imaging

M. L. Malosio, A. Esposito, A. Poletti, S. Chiaretti, L. Piemonti, R. Melzi, R. Nano, F. Tedoldi, T. Canu, P. Santambrogio, C. Brigatti, F. De Cobelli, P. Maffi, A. Secchi, A. Del Maschio

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Islet transplantation is an effective therapy for restoring normoglycemia in type-1 diabetes, but long-term islet graft function is achieved only in a minority of cases. Noninvasive magnetic resonance imaging of pancreatic islets is an attractive option for "real-time" monitoring of graft evolution. So far, previous studies have been performed in the absence of a standardized labeling procedure and, besides a feasibility study in patients, the effectiveness and safety of various labeling approaches were tested only with high field magnets (4.7 T). In this study, we addressed: (a) standardization of a labeling procedure for human islets with clinically-approved contrast agent Endorem®, (b) safety aspects of labeling related to inflammation and (c) quality of imaging both at 7 T and 1.5 T. We have highlighted that the ratio of Endorem®/islet is crucial for reproducible labeling, with a ratio of 2.24 ug/IEQ, allowing successful in vivo imaging both with 1.5 T and 7.0 T magnets up to 143 days after intrahepatic transplant. With this standardized labeling procedure, labeled islets are neither inflamed nor more susceptible to inflammatory insults than unlabeled ones. This report represents an important contribution towards the development of a standardized and safe clinical protocol for the noninvasive imaging of transplanted islets in humans.

Original languageEnglish
Pages (from-to)2372-2382
Number of pages11
JournalAmerican Journal of Transplantation
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Magnets
Magnetic Resonance Imaging
Transplants
Islets of Langerhans Transplantation
Feasibility Studies
Patient Safety
Clinical Protocols
Type 1 Diabetes Mellitus
Islets of Langerhans
Contrast Media
Inflammation
Safety
ferumoxides
Therapeutics

Keywords

  • IL6
  • Magnetic resonance imaging (MRI)
  • MCP-1
  • Pancreatic islet transplantation
  • Proinflammatory cytokines
  • Superparamagnetic iron oxide contrast agents

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

@article{2b128e654b484430a41cf46d71b32f9f,
title = "Improving the procedure for detection of intrahepatic transplanted islets by magnetic resonance imaging",
abstract = "Islet transplantation is an effective therapy for restoring normoglycemia in type-1 diabetes, but long-term islet graft function is achieved only in a minority of cases. Noninvasive magnetic resonance imaging of pancreatic islets is an attractive option for {"}real-time{"} monitoring of graft evolution. So far, previous studies have been performed in the absence of a standardized labeling procedure and, besides a feasibility study in patients, the effectiveness and safety of various labeling approaches were tested only with high field magnets (4.7 T). In this study, we addressed: (a) standardization of a labeling procedure for human islets with clinically-approved contrast agent Endorem{\circledR}, (b) safety aspects of labeling related to inflammation and (c) quality of imaging both at 7 T and 1.5 T. We have highlighted that the ratio of Endorem{\circledR}/islet is crucial for reproducible labeling, with a ratio of 2.24 ug/IEQ, allowing successful in vivo imaging both with 1.5 T and 7.0 T magnets up to 143 days after intrahepatic transplant. With this standardized labeling procedure, labeled islets are neither inflamed nor more susceptible to inflammatory insults than unlabeled ones. This report represents an important contribution towards the development of a standardized and safe clinical protocol for the noninvasive imaging of transplanted islets in humans.",
keywords = "IL6, Magnetic resonance imaging (MRI), MCP-1, Pancreatic islet transplantation, Proinflammatory cytokines, Superparamagnetic iron oxide contrast agents",
author = "Malosio, {M. L.} and A. Esposito and A. Poletti and S. Chiaretti and L. Piemonti and R. Melzi and R. Nano and F. Tedoldi and T. Canu and P. Santambrogio and C. Brigatti and {De Cobelli}, F. and P. Maffi and A. Secchi and {Del Maschio}, A.",
year = "2009",
month = "10",
doi = "10.1111/j.1600-6143.2009.02791.x",
language = "English",
volume = "9",
pages = "2372--2382",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Improving the procedure for detection of intrahepatic transplanted islets by magnetic resonance imaging

AU - Malosio, M. L.

AU - Esposito, A.

AU - Poletti, A.

AU - Chiaretti, S.

AU - Piemonti, L.

AU - Melzi, R.

AU - Nano, R.

AU - Tedoldi, F.

AU - Canu, T.

AU - Santambrogio, P.

AU - Brigatti, C.

AU - De Cobelli, F.

AU - Maffi, P.

AU - Secchi, A.

AU - Del Maschio, A.

PY - 2009/10

Y1 - 2009/10

N2 - Islet transplantation is an effective therapy for restoring normoglycemia in type-1 diabetes, but long-term islet graft function is achieved only in a minority of cases. Noninvasive magnetic resonance imaging of pancreatic islets is an attractive option for "real-time" monitoring of graft evolution. So far, previous studies have been performed in the absence of a standardized labeling procedure and, besides a feasibility study in patients, the effectiveness and safety of various labeling approaches were tested only with high field magnets (4.7 T). In this study, we addressed: (a) standardization of a labeling procedure for human islets with clinically-approved contrast agent Endorem®, (b) safety aspects of labeling related to inflammation and (c) quality of imaging both at 7 T and 1.5 T. We have highlighted that the ratio of Endorem®/islet is crucial for reproducible labeling, with a ratio of 2.24 ug/IEQ, allowing successful in vivo imaging both with 1.5 T and 7.0 T magnets up to 143 days after intrahepatic transplant. With this standardized labeling procedure, labeled islets are neither inflamed nor more susceptible to inflammatory insults than unlabeled ones. This report represents an important contribution towards the development of a standardized and safe clinical protocol for the noninvasive imaging of transplanted islets in humans.

AB - Islet transplantation is an effective therapy for restoring normoglycemia in type-1 diabetes, but long-term islet graft function is achieved only in a minority of cases. Noninvasive magnetic resonance imaging of pancreatic islets is an attractive option for "real-time" monitoring of graft evolution. So far, previous studies have been performed in the absence of a standardized labeling procedure and, besides a feasibility study in patients, the effectiveness and safety of various labeling approaches were tested only with high field magnets (4.7 T). In this study, we addressed: (a) standardization of a labeling procedure for human islets with clinically-approved contrast agent Endorem®, (b) safety aspects of labeling related to inflammation and (c) quality of imaging both at 7 T and 1.5 T. We have highlighted that the ratio of Endorem®/islet is crucial for reproducible labeling, with a ratio of 2.24 ug/IEQ, allowing successful in vivo imaging both with 1.5 T and 7.0 T magnets up to 143 days after intrahepatic transplant. With this standardized labeling procedure, labeled islets are neither inflamed nor more susceptible to inflammatory insults than unlabeled ones. This report represents an important contribution towards the development of a standardized and safe clinical protocol for the noninvasive imaging of transplanted islets in humans.

KW - IL6

KW - Magnetic resonance imaging (MRI)

KW - MCP-1

KW - Pancreatic islet transplantation

KW - Proinflammatory cytokines

KW - Superparamagnetic iron oxide contrast agents

UR - http://www.scopus.com/inward/record.url?scp=70349221587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349221587&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02791.x

DO - 10.1111/j.1600-6143.2009.02791.x

M3 - Article

C2 - 19681816

AN - SCOPUS:70349221587

VL - 9

SP - 2372

EP - 2382

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -